肝门部胆管癌三维可视化精准诊治中国专家共识(2019版)

2020-03-15 中华医学会数字医学分会 中国实用外科杂志.2020,40(3):260-266.

肝门部胆管癌三维可视化是指用于显示、描述和解释肝门部胆管癌三维解剖和形态特征的一种工具。它借助CT或MRI图像数据,利用计算机图像处理技术对数据进行分析、融合、计算、分割、渲染等,将肝脏、胆道、血管、

中文标题:

肝门部胆管癌三维可视化精准诊治中国专家共识(2019版)

发布日期:

2020-03-15

简要介绍:

肝门部胆管癌三维可视化是指用于显示、描述和解释肝门部胆管癌三维解剖和形态特征的一种工具。它借助CT或MRI图像数据,利用计算机图像处理技术对数据进行分析、融合、计算、分割、渲染等,将肝脏、胆道、血管、肿瘤等目标的形态、空间分布等进行描述和解释,并可直观、准确、快捷地将目标从视觉上分离出来,为术前准确诊断、手术方案个体化规划和手术入路选择提供决策。为了规范三维可视化、3D打印、虚拟现实、荧光影像等技术在肝门部胆管癌精准诊疗的应用,中华医学会数字医学分会、中国研究型医院学会数字智能化外科专业委员会、中华医学会外科学分会胆道外科学组等组织国内相关领域的专家,对2017年版《肝门部胆管癌三维可视化精准诊治专家共识》进行修订。

 

下载附件:

(因为版权问题,不支持下载)

评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2154621, encodeId=b37c215462131, content=想读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3038352732, createdName=ms6000001241458526, createdTime=Fri Aug 25 23:05:13 CST 2023, time=2023-08-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1228240, encodeId=8805122824074, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Thu Jun 23 16:33:15 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056464, encodeId=eb5f10564640e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c595609897, createdName=ms5000001043430616, createdTime=Thu Sep 30 12:55:10 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974478, encodeId=e7a69e447834, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210617/265950135a2e48f1bf1b8f368649d550/a272c8f57f32484e8b8ae392d027e221.jpg, createdBy=d6585527950, createdName=渴求, createdTime=Thu Jun 17 20:51:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958809, encodeId=9fcf958809ec, content=学习了,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92455482358, createdName=ms9000001980664381, createdTime=Tue Apr 20 18:07:27 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2023-08-25 ms6000001241458526 来自浙江省

    想读

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2154621, encodeId=b37c215462131, content=想读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3038352732, createdName=ms6000001241458526, createdTime=Fri Aug 25 23:05:13 CST 2023, time=2023-08-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1228240, encodeId=8805122824074, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Thu Jun 23 16:33:15 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056464, encodeId=eb5f10564640e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c595609897, createdName=ms5000001043430616, createdTime=Thu Sep 30 12:55:10 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974478, encodeId=e7a69e447834, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210617/265950135a2e48f1bf1b8f368649d550/a272c8f57f32484e8b8ae392d027e221.jpg, createdBy=d6585527950, createdName=渴求, createdTime=Thu Jun 17 20:51:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958809, encodeId=9fcf958809ec, content=学习了,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92455482358, createdName=ms9000001980664381, createdTime=Tue Apr 20 18:07:27 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2022-06-23 145d4c03m99暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2154621, encodeId=b37c215462131, content=想读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3038352732, createdName=ms6000001241458526, createdTime=Fri Aug 25 23:05:13 CST 2023, time=2023-08-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1228240, encodeId=8805122824074, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Thu Jun 23 16:33:15 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056464, encodeId=eb5f10564640e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c595609897, createdName=ms5000001043430616, createdTime=Thu Sep 30 12:55:10 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974478, encodeId=e7a69e447834, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210617/265950135a2e48f1bf1b8f368649d550/a272c8f57f32484e8b8ae392d027e221.jpg, createdBy=d6585527950, createdName=渴求, createdTime=Thu Jun 17 20:51:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958809, encodeId=9fcf958809ec, content=学习了,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92455482358, createdName=ms9000001980664381, createdTime=Tue Apr 20 18:07:27 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-09-30 ms5000001043430616

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2154621, encodeId=b37c215462131, content=想读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3038352732, createdName=ms6000001241458526, createdTime=Fri Aug 25 23:05:13 CST 2023, time=2023-08-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1228240, encodeId=8805122824074, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Thu Jun 23 16:33:15 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056464, encodeId=eb5f10564640e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c595609897, createdName=ms5000001043430616, createdTime=Thu Sep 30 12:55:10 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974478, encodeId=e7a69e447834, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210617/265950135a2e48f1bf1b8f368649d550/a272c8f57f32484e8b8ae392d027e221.jpg, createdBy=d6585527950, createdName=渴求, createdTime=Thu Jun 17 20:51:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958809, encodeId=9fcf958809ec, content=学习了,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92455482358, createdName=ms9000001980664381, createdTime=Tue Apr 20 18:07:27 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-06-17 渴求

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2154621, encodeId=b37c215462131, content=想读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3038352732, createdName=ms6000001241458526, createdTime=Fri Aug 25 23:05:13 CST 2023, time=2023-08-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1228240, encodeId=8805122824074, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Thu Jun 23 16:33:15 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056464, encodeId=eb5f10564640e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c595609897, createdName=ms5000001043430616, createdTime=Thu Sep 30 12:55:10 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974478, encodeId=e7a69e447834, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210617/265950135a2e48f1bf1b8f368649d550/a272c8f57f32484e8b8ae392d027e221.jpg, createdBy=d6585527950, createdName=渴求, createdTime=Thu Jun 17 20:51:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958809, encodeId=9fcf958809ec, content=学习了,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92455482358, createdName=ms9000001980664381, createdTime=Tue Apr 20 18:07:27 CST 2021, time=2021-04-20, status=1, ipAttribution=)]
    2021-04-20 ms9000001980664381

    学习了,

    0

拓展阅读

AHPBA专家共识声明:肝门部胆管癌(2015年)

美国肝胰胆协会(AHPBA,American Hepato-Pancreato-Biliary Association) · 2015-07-10